

# Paula R Pohlmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1396166/publications.pdf>

Version: 2024-02-01

69  
papers

2,352  
citations

394421

19  
h-index

223800

46  
g-index

73  
all docs

73  
docs citations

73  
times ranked

4012  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant platinum-based chemotherapy for early stage cervical cancer. The Cochrane Library, 2022, 2022, CD005342.	2.8	37
2	Abstract PD9-02: Peripheral immune subsets and circulating tumor DNA (ctDNA) in patients (pts) with residual triple negative breast cancer (TNBC) treated with adjuvant immunotherapy and/or chemotherapy (chemo): The OXEL study. Cancer Research, 2022, 82, PD9-02-PD9-02.	0.9	4
3	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. Npj Breast Cancer, 2022, 8, 18.	5.2	8
4	Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux. Cancer and Metastasis Reviews, 2022, 41, 447-458.	5.9	19
5	Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions. Drug Safety, 2022, 45, 601-621.	3.2	10
6	An evaluation of palbociclib as a breast cancer treatment option: a current update. Expert Opinion on Pharmacotherapy, 2021, 22, 281-290.	1.8	3
7	Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function. Breast Cancer Research and Treatment, 2021, 185, 863-868.	2.5	18
8	Abstract OT-03-02: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, as a single agent and in combination with an immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. Cancer Research, 2021, 81, OT-03-02-OT-03-02.	0.9	10
9	Abstract PD3-08: Tucatinib vs placebo in combination with trastuzumab and capecitabine for patients with locally advanced unresectable or HER2-positive metastatic breast cancer (HER2CLIMB): Outcomes by hormone receptor status. , 2021, , .		1
10	Abstract PS4-02: The immune microenvironment of liver metastasis as a guide for immunotherapeutic potential in breast cancer. , 2021, , .		0
11	Abstract PS17-27: Molecular evaluation of immunogenicity and genomic alterations in invasive lobular breast cancer. , 2021, , .		0
12	SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).. Journal of Clinical Oncology, 2021, 39, TPS3151-TPS3151.	1.6	2
13	Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.. Journal of Clinical Oncology, 2021, 39, TPS1111-TPS1111.	1.6	0
14	Hematologic safety of palbociclib in combination with endocrine therapy in patients with benign ethnic neutropenia and advanced breast cancer. Cancer, 2021, 127, 3622-3630.	4.1	8
15	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Research and Treatment, 2021, 189, 103-110.	2.5	19
16	Abstract CT218: Phase 1/2 study of a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), BDC-1001, alone and in combination with pembrolizumab (pembro) in patients (pts) with HER2-expressing advanced solid tumors. Cancer Research, 2021, 81, CT218-CT218.	0.9	2
17	Abstract 585: A robust method for expanding patient-derived circulating tumor cellsex vivo. , 2021, , .		0
18	Abstract CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16). , 2021, , .		0

#	ARTICLE	IF	CITATIONS
19	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	1.6	76
20	Circulating Tumor Cells: Technologies and Their Clinical Potential in Cancer Metastasis. <i>Biomedicines</i> , 2021, 9, 1111.	3.2	25
21	Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 131.	5.2	13
22	Efficient Propagation of Circulating Tumor Cells: A First Step for Probing Tumor Metastasis. <i>Cancers</i> , 2020, 12, 2784.	3.7	14
23	Actionable co-alterations in breast tumors with pathogenic mutations in the homologous recombination DNA damage repair pathway. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 265-275.	2.5	22
24	O82â€¦A phase 1 dose escalation study of PRS-343, a HER2/4â€œ1BB bispecific molecule, in patients with HER2-positive malignancies. , 2020, , .		21
25	Prevalence of Phosphatidylinositol-3-Kinase (PI3K) Pathway Alterations and Co-alteration of Other Molecular Markers in Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1475.	2.8	11
26	Rebound lymphocytosis in a patient with chronic lymphocytic leukemia after cessation of a CDK 4/6 inhibitor for concomitant breast cancer. <i>Breast Journal</i> , 2020, 26, 2031-2033.	1.0	2
27	401â€¦Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors. , 2020, , .		2
28	Abstract OT2-03-04: A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study. , 2020, , .		1
29	Abstract OT2-04-05: Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. , 2020, , .		1
30	Abstract P1-19-20: Safety of palbociclib in African American women with hormone receptor positive HER2 negative advanced breast cancer and benign ethnic neutropenia: PALINA study. , 2020, , .		0
31	Abstract P4-09-05: Somatic genomic profiles of breast tumors differ byBRCA1andBRCA2variants of unknown significance status. , 2020, , .		0
32	Abstract P6-10-06: Amsterdam 70-gene profile (MammaPrint) low risk, even in the HER2 positive subset, identifies a population of women with lower early risk for recurrence despite low response rates to chemotherapy and to HER2 targeted therapy. , 2020, , .		0
33	Abstract P4-09-04: Prevalence of phosphatidylinositol-3-kinase (PI3K) pathway alterations and co-alteration of other markers in breast cancer. , 2020, , .		0
34	Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer. , 2020, , .		0
35	CTNI-02. TBCRC049: A PHASE II STUDY TO ASSESS THE SAFETY AND EFFICACY OF THE COMBINATION OF TUCATINIB, TRASTUZUMAB AND CAPECITABINE FOR THE TREATMENT OF LEPTOMENINGEAL METASTASIS IN HER2 POSITIVE BR1AST CANCER. <i>Neuro-Oncology</i> , 2020, 22, ii41-ii41.	1.2	0
36	A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients. <i>JAMIA Open</i> , 2019, 2, 505-515.	2.0	56

#	ARTICLE	IF	CITATIONS
37	A phase I study of HER1, HER2 dual kinase inhibitor lapatinib plus the proteasome inhibitor bortezomib in patients with advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1145-1151.	2.3	3
38	Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 595-603.	2.5	106
39	TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. <i>Journal of Clinical Oncology</i> , 2019, 37, 1081-1089.	1.6	251
40	Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up. <i>JAMA Oncology</i> , 2019, 5, 334.	7.1	206
41	Characteristics and outcomes of breast cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase I clinical trials. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 35-41.	2.5	7
42	Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few. <i>Journal of the National Cancer Institute</i> , 2018, 110, 3-5.	6.3	3
43	PALINA: A phase II safety study of palbociclib in combination with letrozole or fulvestrant in African American women with hormone receptor positive HER2 negative advanced breast cancer. <i>Contemporary Clinical Trials Communications</i> , 2018, 10, 190-192.	1.1	7
44	Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint. <i>Npj Breast Cancer</i> , 2018, 4, 26.	5.2	24
45	Abstract 907: Targeting glycolysis enzyme, PFKFB3, in endocrine therapy resistant breast cancers. <i>Cancer Research</i> , 2018, 78, 907-907.	0.9	4
46	Abstract CT028: Atezolizumab (atezo) + nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a phase IIb trial. , 2018, , .		3
47	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2488-2499.	0.9	178
48	Coping with Metastatic Breast Cancer: The Patients'™ Perspective in a Brazilian Cancer Center. <i>Breast</i> , 2017, 36, S38.	2.2	2
49	HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens. <i>Clinical Breast Cancer</i> , 2017, 17, 76-78.	2.4	16
50	Video intervention increases participation of black breast cancer patients in therapeutic trials. <i>Npj Breast Cancer</i> , 2017, 3, 36.	5.2	15
51	Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors. <i>PLoS ONE</i> , 2017, 12, e0186190.	2.5	24
52	Abstract B90: PFK-158 is a first-in-human inhibitor of PFKFB3 that selectively suppresses glucose metabolism of cancer cells and inhibits the immunosuppressive Th17 cells and MDSCs in advanced cancer patients. , 2016, , .		4
53	Abstract CT206: PFK-158, first-in-man and first-in-class inhibitor of PFKFB3/ glycolysis: A phase I, dose escalation, multi-center study in patients with advanced solid malignancies. <i>Cancer Research</i> , 2015, 75, CT206-CT206.	0.9	11
54	Optical Metabolic Imaging of Treatment Response in Human Head and Neck Squamous Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e90746.	2.5	72

#	ARTICLE	IF	CITATIONS
55	Quantitative Autofluorescence Imaging Measures Early Response to Head and Neck Cancer Treatment In Vivo. , 2014, , .		0
56	Adjuvant platinum-based chemotherapy for early stage cervical cancer. , 2012, , CD005342.		29
57	Insulin-like growth factor-1 receptor inhibitor, AMG479, in cetuximab-refractory head and neck squamous cell carcinoma. Head and Neck, 2011, 33, 1804-1808.	2.0	16
58	Regulation of Heparin-Binding EGF-Like Growth Factor by miR-212 and Acquired Cetuximab-Resistance in Head and Neck Squamous Cell Carcinoma. PLoS ONE, 2010, 5, e12702.	2.5	128
59	Resistance to Trastuzumab in Breast Cancer. Clinical Cancer Research, 2009, 15, 7479-7491.	7.0	397
60	Chemotherapy and Immunotherapy in Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 2134-2136.	27.0	5
61	A model to optimize public health care and downstage breast cancer in limited-resource populations in southern Brazil. (Porto Alegre Breast Health Intervention Cohort). BMC Public Health, 2009, 9, 83.	2.9	20
62	Adjuvant platinum-based chemotherapy for early stage cervical cancer. , 2009, , CD005342.		47
63	Does peritransplantation use of rituximab reduce the risk of EBV reactivation and PTLPD?. Blood, 2009, 113, 6263-6264.	1.4	21
64	Tumor Size as a Surrogate End Point for the Detection of Early Breast Cancer: A 30-Year (1972-2002), Single-Center Experience in Southern Brazil. Breast Journal, 2007, 13, 448-456.	1.0	13
65	CXCL8 secretion by dendritic cells predicts contact allergens from irritants. Toxicology in Vitro, 2006, 20, 117-124.	2.4	93
66	A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational New Drugs, 2006, 24, 403-412.	2.6	69
67	Accuracy of frozen-section analysis in the diagnosis of ovarian tumors: a systematic quantitative review. International Journal of Gynecological Cancer, 2005, 15, 192-202.	2.5	86
68	Induction of p53 Up-Regulated Modulator of Apoptosis Messenger RNA by Chemotherapeutic Treatment of Locally Advanced Breast Cancer. Clinical Cancer Research, 2005, 11, 1863-1869.	7.0	20
69	Phase II Trial of Cisplatin Plus Decitabine, a New DNA Hypomethylating Agent, in Patients With Advanced Squamous Cell Carcinoma of the Cervix. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 496-501.	1.3	81